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Abstract
Background: The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite
protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water
emulsion – based formulation (AS02) and a formulation based on liposomes (AS01).
Methods & Principal Findings: In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18
months to 4 years were randomized to receive either RTS,S/AS01E or RTS,S/AS02D, on a 0–1–2 month vaccination schedule.
The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were
collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two
groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers
(AS02D/AS01E) of 0.88 (95% CI: 0.68–1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs
antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine
compared to those not previously vaccinated.
Conclusions: RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS,S/AS02D, completing an essential step
in the age de-escalation process within the RTS,S clinical development plan.
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Introduction
The disastrous medical, social and economical burden of
malaria in populations of sub-Saharan Africa is well recognized
[1,2]. The development of an effective malaria vaccine would be
an important addition to existing malaria control strategies.
The pre-erythrocytic stage Plasmodium falciparum antigen RTS,S
is the furthest advanced malaria vaccine candidate in clinical
development [3]. A collaborative partnership involving several
malaria research institutions worldwide, GlaxoSmithKline Biolog-
icals (GSK), the PATH Malaria Vaccine Initiative and the Malaria
Clinical Trial Alliance was developed with the goal to develop
RTS,S/AS for the Expanded Program on Immunisation (EPI) of
the World Health Organization [4].
RTS,S is a hybrid molecule recombinantly expressed in yeast, in
which the central tandem repeat and carboxyl-terminal region of
the circumsporozoite protein are fused to the N-terminal of the S-
antigen of the Hepatitis B virus, creating a particle that also
includes the unfused S-antigen. RTS,S is formulated in Adjuvant
Systems which enhance the ability of the vaccine to induce a
strong immune response. The AS02 Adjuvant System contains an
oil-in-water emulsion, monophosphoryl lipid A (MPL), and QS21,
a natural saponin molecule purified from the bark of the South
American tree, Quillaja saponaria. Following Phase I studies, a
Phase IIb efficacy trial conducted in about two thousand
Mozambican children aged 1–4 years showed that the vaccine
reduced the risk of clinical malaria (vaccine efficacy of 35%) and of
severe malaria (vaccine efficacy of 49%) over a period of 18
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months [5]. In infants from the same study area receiving the
vaccine at 10, 14, and 18 weeks of age, the risk of infection was
reduced by 65% over three months after the third and final dose
and the risk of clinical disease by 35% over a six-month period
following the first dose [6].
In addition to the oil-in-water emulsion of AS02, an alternative
Adjuvant System based on liposomes and containing the same
amounts of MPL and QS21 has been developed (AS01). An initial
study in malaria-naı¨ve adults showed that RTS,S/AS01 had a
similar safety profile, a higher humoral immunogenicity, a
favorable Th1 cell mediated immune profile and a trend towards
higher vaccine efficacy in comparison to RTS,S/AS02 [7].
AS01 and AS02 have been formulated in both adult (AS01B,
AS02A) and pediatric (AS01E, AS02D) dosages. In the large
Phase II trial in Mozambique [8] the pediatric dosage was
obtained by administering half of the adult dose (i.e. 0.25 mL of
AS02A). In order to comply with EPI standards, the vaccine
volume was changed to 0.5 mL. The equivalency of 0.25 mL
AS02A and 0.5 mL AS02D, both containing 25 mg RTS,S, in
terms of safety and immunogenicity was shown in children in
Mozambique [9].
As part of an age de-escalation step in the RTS,S clinical
vaccine development plan, we conducted a phase II, randomized,
double-blind study to assess the safety and immunogenicity of
RTS,S/AS01E and RTS,S/AS02D in children aged 18 months to
4 years living in Gabon. The resulting data will make a significant
contribution in deciding which Adjuvant System to use for a large
scale large efficacy trial with RTS,S/AS. Furthermore, we hoped
to obtain information on the immunogenic effect of the third dose,
compared to two doses, and the effect of previous hepatitis B
immunisation on the anti-CS immune response.
Materials and Methods
The protocol for this trial [http://clinicaltrials.gov/:
NCT00307021] and supporting CONSORT checklist are avail-
able as supporting information; see Checklist S1 and Protocol S1.
Ethics statement
The study protocol was approved by the ethics committee of the
International Foundation of the Albert Schweitzer Hospital of
Lambare´ne´ and the Western Institutional Review Board, USA.
The trial was undertaken according to the International
Conference on Harmonisation of Good Clinical Practice guide-
lines and was monitored by GSK Biologicals, Rixensart, Belgium.
A local safety monitor and a data and safety monitoring board
closely reviewed the conduct and results of the trial. After
vaccination of Dose 1 and Dose 2 of the first 30 subjects, the data
and safety monitoring board reviewed the seven day post
vaccination safety data in order to decide on the continuation to
the next dose.
Study site
The study lasted from April 2006 to August 2007 and was
conducted at the Medical Research Unit (MRU) of Albert
Schweitzer Hospital in Lambare´ne´, located in the central part of
Gabon. Malaria transmission is mainly attributable to Plasmodium
falciparum. Anopheles gambiae is the main vector and transmission is
perennial, moderate to high in intensity [10], with an average
entomological inoculation rate (EIR) around 50 infective bites per
person per year [11].The incidence of malaria in children was
around 1.5 per child per year in 1999 [12], but has decreased in
recent years [13]. Long-lasting insecticide-treated bednets are
provided free of charge for pregnant women and children under
12 months of age during national health campaigns. A study
carried out in 2005 revealed a high proportion of the population
sleeping under bednets, however these often had never been
impregnated (94%) and had holes (20%) [14].
Coverage of routine EPI vaccination in the study area is above
national average [15] with a recent survey showing 87% of
children having received three doses of DTP at 4 months of age
and 74% had received measles vaccination at 9 months of age
(Bertrand Lell, unpublished data).
Study design
This was a Phase II randomized, double-blind trial to describe
safety, reactogenicity and immunogenicity of RTS,S/AS01E and
RTS,S/AS02D when administered intramuscularly with a 0, 1, 2
month vaccination schedule in children aged 18 months to 4 years.
The primary objectives were to assess the occurrence of serious
adverse events from the time of first vaccination until one month
post Dose 3 and to establish the non-inferiority of anti
circumsporozoite antibodies titers of RTS,S/AS01E compared to
RTS,S/AS02D at one month post Dose 3. A SAE was defined per
protocol as any untoward medical occurrence that was fatal, life-
threatening, required hospitalization, led to disability or incapac-
ity, or was judged by investigators as being medically important
enough to be reported as serious. In order to maximize data
capture about seizures, all seizures occurring within 30 days of
vaccination had to be reported as SAEs. Data on seizures
occurring within 7 days post vaccination were collected in a
standard way according to Brighton collaboration guidelines [16].
Secondary objectives included reactogenicity, anti-HBs anti-
body response and anti-CS response, and the 1 year post last dose
safety and immunogenicity follow up.
Study vaccines
RTS,S/AS02D (0.5 mL) and RTS,S/AS01E (0.5 mL) comprise
the RTS,S antigen presented as a lyophilized pellet, which is
reconstituted prior to injection with 0.5 mL of AS02D or AS01E
liquid Adjuvant Systems containing MPL and QS21 immuno-
stimulants. The RTS,S pellet and Adjuvant Systems are in sterile
glass vials, stored between +2 and +8uC.
Study population
We included children aged 18 months to 4 years (up to but not
including 5th birthday) who were permanent residents in
Lambare´ne´. Written informed consent or, in case of illiteracy,
a thumb print in presence of a literate witness was obtained for all
screened children from both parents/guardians, or at least one
parent in case the other could not be reached. Major exclusion
criteria were history of allergic disease, a weight for age Z-
score less than 22, and clinically significant chronic or acute
disease.
Randomization and blinding
Eligible children were allocated to a treatment group on the day
of first vaccination. The randomization list, designed as a single
block randomization, was generated at GSK Biologicals, Rix-
ensart, using SASH statistical software. Safety and immunogenicity
endpoints were evaluated in a double-blind manner as the
investigators and their parent(s)/guardian(s) were unaware which
vaccine was administered to a particular child. Only two study
nurses and an observer responsible for vaccine storage, prepara-
tion and quality control were aware of the vaccine assignment.
They were not involved in other aspects of the trial or patient care.
Code break envelopes with individual vaccine allocation were kept
RTS,S Vaccine in Children
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locally with a local safety monitor. A second copy was kept at GSK
Biologicals, Rixensart, Belgium. There was no case of emergency
unblinding during the study. Vaccine preparation, vaccination and
clinical observation were performed in separated rooms. Vaccine
preparation consisted of reconstituting the lyophilized antigen
using the liquid Adjuvant System fraction, stored in separate vials,
to a final volume of 0.5 mL.
Study procedures
Before screening, the parents or guardian was issued a bednet
containing an impregnation kit and instructions on its use.
Screening procedures included a brief medical history, examina-
tion and blood sampling for hematology (hemoglobin, white cell
count, and platelets), and biochemistry (ALT, creatinine, and
bilirubin). The past Hepatitis B immunization status as docu-
mented on the children’s national immunization cards was
recorded. Vaccine administration was by slow IM injection in
the left deltoid. After vaccination, children were observed for at
least one hour by investigators trained in pediatric emergency care
and thereafter visited by field workers daily for the next six days.
General symptoms and those specific to RTS,S vaccination in
particular were assessed. These ‘solicited symptoms’ (local
symptoms: pain, swelling; generalized symptoms: drowsiness,
fever, irritability, loss of appetite) were graded and recorded on
diary cards. Grade 3 symptoms were defined, for pain, when a
child cries when limb is moved or spontaneously painful; for
swelling when larger than 20 mm; and for general symptoms, as
those that prevent normal activities. Unsolicited adverse events
were documented over a period of 30 days post vaccination and
serious adverse events were recorded up to one year post last
vaccine dose. Local standard medical care was provided free of
charge throughout the study.
Laboratory methods
As part of safety assessments, venous blood samples were
collected for hematology (hemoglobin, white cell count, platelets;
ABX Pentra 60 analyzer, France) and biochemistry (ALT,
creatinine and bilirubin; Cobra Mira Plus analyzer, Switzerland)
determination on Day 6 after Dose 1 and one month post Dose 3.
Blood samples for the measurement of anti-circumsporozoite
protein (CS) and antibody to the hepatitis B surface antigen (anti-
HBsAg) were collected at screening and one month post Dose 2
and 3, and at study month 14. Serological responses to CS repeats
(anti R32LR) were assessed by standard ELISA methodology
using a plate adsorbed R32LR antigen with a standard reference
antibody as a control with concentrations reported as EU/mL.
Antibody titers to hepatitis B surface antigen were measured using
an ELISA immunoassay, developed at GSK Biologicals, Rixensart
with concentrations reported in mIU/mL. All ELISA assays were
performed in a GLP ICH validated laboratory.
Figure 1. Subject disposition.
doi:10.1371/journal.pone.0007611.g001
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Populations analyzed
The ITT cohort for analysis of safety included all subjects who
received at least one vaccine dose. The ATP cohort for analysis of
immunogenicity included all evaluable subjects (i.e., those meeting
all eligibility criteria, complying with the procedures defined in the
protocol, having no elimination criteria during the study) for
whom data concerning immunogenicity endpoint measures were
available.
Statistical analysis
A sample size of 75 evaluable subjects per group was
determined to have 90% power to demonstrate non-inferiority
of RTS,S/AS01E versus RTS,S/AS02D in terms of anti-CS
immune response (upper limit of 95% CI of the GMT ratio
RTS,S/AS02D versus RTS,S/AS01E below 3.0), assuming a log
standard deviation of 0.9 in both groups, and an alpha level of
2.5%. To allow for loss to follow-up, 90 children were included in
each group. The Geometric Mean Titers (GMTs) calculations
were performed by taking the anti-log of the mean of the log10
titer transformations. The 95% CI of the ratio of anti-CS GMTs
was calculated using a one-way ANOVA model on the logarithm
transformation of the titers. Antibody titers below the cut-off of the
assay were given an arbitrary value of half the cut-off for the
purpose of GMT calculation. Subjects with anti-HBs antibody
titers greater than 10 mIU/mL were considered protected.
Results
Out of 280 children screened for eligibility, 180 were
randomized into two intervention groups. The demographic
characteristics were similar in the two groups, with a mean age
of 39.6 (SD: 11.5) months and 39.3 (SD: 11.2) months and with 36
(40%) and 52 (58%) females in the RTS,S/AS01E and the RTS,S/
AS02D group, respectively. Figure 1 shows the disposition of
subjects in the study.
Safety
The vaccine safety was analyzed based on the 180 children of the
ITT population. Between first vaccination and 1 month post Dose
3, three children in the RTS,S/AS01E group and four in the
Table 1. Listing of SAEs that occurred during the whole study period.
Group Subject No. Gender
Age at onset
(Month) Event (Preferred term) Onset (days post Dose) Vaccine relatedness
AS01E 9 M 33 Febrile convulsion 18d post D2 No
Pyrexia 17d post D2 No
66 M 58 Hydrocele 272d post D3 No
Phimosis 272d post D3 No
104 M 37 Constipation 97d post D3 No
115 M 57 Bronchitis 286d post D3 No
125 F 28 Pneumonia 216d post D3 No
181 M 30 Anaemia 7d post D3 No
Asthma 7d post D3 No
Pneumonia 6d post D3 No
234 F 42 Anaemia 101d post D3 No
Malaria 96d post D3 No
277 F 51 Hepatitis A 2d post D2 No
Sickle cell anaemia 5d post D2 No
AS02D 1 M 33 Umbilical hernia, obstructive 21d post D2 No
72 F 34 Asthma 81d post D3 No
Lower respiratory tract infection 77d post D3 No
Pharyngitis 77d post D3 No
88 F 25 Gastroenteritis 26d post D3 No
28 Burns second degree 122d post D3 No
117 F 40 Anaemia 47d post D3 No
Cerebral malaria 42d post D3 No
42 Plasmodium falciparum infection 92d post D3 No
138 F 27 Gastroenteritis 30d post D3 No
141 M 22 Gastroenteritis 9d post D3 No
161 M 30 Asthma 126d post D3 No
33 Pneumonia 230d post D3 No
198 M 38 Epilepsy 84d post D3 No
44 Epilepsy 238d post D3 No
45 Epilepsy 273d post D3 No
doi:10.1371/journal.pone.0007611.t001
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RTS,S/AS02D group experienced at least one serious adverse event
(Table 1),. Two children were excluded from further vaccination
due to a serious adverse event, diagnosed with conditions that would
have precluded study participation if found before enrolment: one
case of newly diagnosed sickle cell, and one case of a simple febrile
convulsion that occurred 18 days postvaccination, in the context of
an uncharacterized acute febrile illness that evolved favorably over 3
days. The other serious adverse events included anemia, asthma,
gastroenteritis, pneumonia, and incarcerated umbilical hernia.
Between first vaccination and study Month 14, 16 subjects
experienced at least one serious adverse events (8 in each group)
(Table 1). None of these events were considered related to the study
vaccine and all subjects recovered.
Solicited adverse events are summarized in Table 2. Mild local
solicited symptoms were frequent with pain being reported
following 48% and 54% of doses of RTS/AS01E and RTS,S/
AS02D respectively and swelling being present following 32% and
37% of doses of RTS/AS01E and RTS,S/AS02D. Grade 3
symptoms were rare, being present only after two vaccine doses
administered. These were two cases of swelling over 20 mm, one
in each study group. There was an increase in the frequency of
local symptoms for subsequent doses for both groups. General
solicited symptoms were considerably less frequent, with loss of
Table 2. Solicited symptoms per dose during a 7-days post-
vaccination period.
RTS,S/AS01E RTS,S/AS02D
N n (%; 95%CI) N n (%; 95%CI)
Generalized
symptoms:
Drowsiness, overall 261 17 (7%; 4–10%) 262 13 (5%; 3–8%)
Fever, overall 261 15 (6%; 3–9%) 262 23 (9%; 6–13%)
Irritability, overall 261 6 (2%; 1–5%) 262 8 (3%; 1–6%)
Loss of appetite, overall 261 44 (17%; 13–22%) 262 46 (18%; 13–23%)
Local symptoms:
Pain, overall 261 126 (48%; 42–55%) 262 142 (54%; 48–60%)
Dose 1 90 19 (21%; 13–31%) 90 32 (36%; 26–46%)
Dose 2 88 34 (39%; 28–50%) 87 34 (39%; 29–50%)
Dose 3 83 73 (88%; 79–94%) 85 76 (89%; 81–95%)
Swelling, overall 261 83 (32%; 26–38%) 262 96 (37%; 31–43%)
Dose 1 90 5 (6%; 2–13%) 90 13 (14%; 8–23%)
Dose 2 88 21 (24%; 15–34%) 87 22 (25%; 17–36%)
Dose 3 83 57 (69%; 58–78%) 85 61 (72%; 61–81%)
N: number of vaccine doses administered.
doi:10.1371/journal.pone.0007611.t002
Table 3. Occurrence of unsolicited symptoms within the 30-
day (Days 0–29) post-vaccination period.
RTS,S/AS01E RTS,S/AS02D
N=90 95% CI N=90 95% CI
Preferred Term n % LL UL n % LL UL
At least one event 71 78.9 69.0 86.8 74 82.2 72.7 89.5
Diarrhoea 5 5.6 1.8 12.5 9 10.0 4.7 18.1
Pyrexia 5 5.6 1.8 12.5 5 5.6 1.8 12.5
Acarodermatitis 5 5.6 1.8 12.5 6 6.7 2.5 13.9
Bronchitis 9 10.0 4.7 18.1 11 12.2 6.3 20.8
Gastroenteritis 4 4.4 1.2 11.0 9 10.0 4.7 18.1
Helminthic infection 17 18.9 11.4 28.5 11 12.2 6.3 20.8
Nasopharyngitis 41 45.6 35.0 56.4 41 45.6 35.0 56.4
Otitis media 5 5.6 1.8 12.5 2 2.2 0.3 7.8
Staphylococcal skin
infection
10 11.1 5.5 19.5 13 14.4 7.9 23.4
Tinea capitis 6 6.7 2.5 13.9 5 5.6 1.8 12.5
Upper respiratory tract
infection
5 5.6 1.8 12.5 4 4.4 1.2 11.0
Percentage of subjects reporting the occurrence of unsolicited symptoms
classified by MEDDRA Preferred Term within the 30-day (Days 0–29) post-
vaccination period, for events that occurred in over 5% of the patient in at least
one of the study groups.
N = number of subjects with at least one administered vaccine dose.
n/%=number/percentage of subjects reporting at least once the symptom.
95% CI = exact 95% confidence interval; LL = Lower Limit, UL =Upper Limit.
doi:10.1371/journal.pone.0007611.t003
Table 4. Anti-CS and anti-HBs antibody titers after each dose
and at 12 months post Dose 3.
RTS,S/AS01E RTS,S/AS02D
N mean 95%CI N mean 95%CI
Anti-CS
antibodies:
Screening, all 85 0.3 0.3–0.3 84 0.3 0.3–0.3
- pre HBV 40 0.3 0.3–0.3 40 0.3 0.3–0.3
- no pre HBV 37 0.3 0.3–0.3 39 0.3 0.2–0.3
Post Dose 2, all 74 80 63–101 74 58 46–73
- pre HBV 35 109 79–152 34 81 57–114
- no pre HBV 31 50 35–71 36 44 33–59
Post Dose 3, all 73 207 172–250 73 183 151–223
- pre HBV 35 238 187–302 36 201 145–278
- no pre HBV 31 170 122–238 33 164 128–209
Month 14, all 58 16 12–21 54 18 13–26
- pre HBV 29 15 10–23 29 18 10–32
- no pre HBV 23 17 10–28 21 17 10–29
Anti-HBs
antibodies:
Screening, all 85 45 25–80 84 19 12–29
- pre HBV 40 284 127–637 40 61 30–124
- no pre HBV 37 8 5–11 39 6 4–9
Post Dose 2, all 74 9228 4676–18210 74 3838 2036–7237
- pre HBV 35 79610 43152–146869 34 22946 10115–52053
- no pre HBV 31 1095 562–2135 36 770 385–1540
Post Dose 3, all 73 26330 16578–41821 73 20068 13636–29533
- pre HBV 35 94879 56708–158741 36 48279 28412–82038
- no pre HBV 31 7982 5534–11511 33 8292 5233–13138
Month 14, all 58 6769 4338–10561 54 5236 3421–8012
- pre HBV 29 17851 10235–31136 29 8408 4467–15825
- no pre HBV 23 2539 1723–3746 21 3100 1708–5625
Values are geometric mean titers and 95% confidence intervals expressed in EU/
mL. N values for pre HBV and no pre HBV do not match up to the total due to
some missing values on the pre HBV status.
doi:10.1371/journal.pone.0007611.t004
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appetite observed most frequently, after 44 (17%) doses of RTS,S/
AS01E and 46 (18%) of RTS,S/AS02D doses. Frequencies of
general solicited symptoms were similar between the intervention
groups and no increase in frequency for progressive doses was
found. No grade 3 solicited generalized symptoms were observed
following vaccination. Previous Hepatitis B vaccination did not
significantly affect the incidence of solicited symptoms following
vaccination with either study vaccine (data not shown).
Overall, unsolicited adverse events in the 30 days post
vaccination period occurred in 78.9% of the participants of the
RTS,S/AS01E group and in 82.2% of the RTS,S/AS02D group
(Table 3). The most frequently observed unsolicited symptoms
were upper respiratory tract infection and other common pediatric
conditions. None were considered to be causally related to the
study vaccines.
Out of range hematological and biochemical values were
observed in 21 measurements. No Grade 3 abnormalities were
observed. The abnormal values were all judged not to be clinically
significant and there was no imbalance between vaccine groups.
Immunogenicity
The antibody response was evaluated in the ATP population,
consisting of 170 children, balanced by group. The primary
immunogenicity endpoint of the trial was met: at 30 days post Dose
3, the ratio of GMT titers (AS02D/AS01E) was 0.88 (95% CI: 0.68–
1.15), with an upper confidence interval below the pre-defined non-
inferiority cut-off of three. Both vaccines elicited a strong specific
immune response after Dose 2 and Dose 3 (Table 4). For both
vaccines, the antibody titers were significantly higher after the third
dose compared to the first two doses. There was a trend towards
higher anti-CS GMTs in the recipients of RTS,S/AS01E compared
to the RTS,S/AS02D group at post Dose 2 and post Dose 3, but
these were of similar magnitude at study Month 14.
In both study groups, an equivalent proportion of children had
previously received hepatitis B vaccination. After Dose 2 and Dose
3 of experimental vaccine, anti-CS antibody GMTs were higher in
the children who had been previously vaccinated with at least one
dose of hepatitis B vaccine compared to those who had not been
previously vaccinated (Table 4, Figure 2). No difference in GMTs
was apparent at study Month 14.
Both RTS,S/AS01E and RTS,S/AS02D were highly immuno-
genic for anti-HBs antibodies. Over 98% of the children had anti-
HBs titers above the seroprotection level following Dose 2 and all
children were protected following Dose 3, with no difference
between groups. There was a trend towards higher anti-HBs
GMTs in the recipients of RTS,S/AS01E compared to the
RTS,S/AS02D group, following both Dose 2 and Dose 3, with a
AS02D/AS01E GMT ratio of 0.76 (95% CI: 0.42–1.39) after the
third dose (Table 4, Figure 3).
Children who had previously received a hepatitis B vaccine had
higher anti-HBs GMTs at screening than those who were not
vaccinated and the difference remained statistically significant at all
Figure 2. The effect of previous hepatitis B vaccination on anti-CS antibodies. Boxplot graph of anti-CS responses. Represents Q25, median,
Q75, highest and lowest observation below/above 1.5 times interquartile range and individual data points below/above 1.5 times interquartile range.
GMTs are indicated by +.
doi:10.1371/journal.pone.0007611.g002
RTS,S Vaccine in Children
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7611
three timepoints for either vaccine. Post Dose 3, GMTs for
recipients of RTS,S/AS01E were 94879 mIU/mL and 7982 mIU/
mL and for recipients of RTS,S/AS02D were 48279 mIU/mL and
8292 mIU/mL with previous hepatitis B vaccination and without
previous hepatitis B vaccination, respectively (Table 4).
Discussion
A series of clinical studies performed with more than a thousand
vaccine recipients have established the RTS,S/AS02 candidate
vaccine to have an promising safety profile and to be well-tolerated.
These studies were conducted in malaria-naı¨ve and semi-immune
adults as well as African children, with the first demonstration of
efficacy for a malaria candidate vaccine [5,8,17–20]. Pre-clinical data
suggests that RTS,S/AS01 may be a better malaria vaccine
candidate [21]. A challenge study conducted in the United States
showed that RTS,S/AS01, as compared to RTS,S/AS02, induced
higher levels of anti-CS antibodies and CS-specific T-cells, and a
trend towards higher protection against infection following experi-
mental sporozoite challenge. The safety profile of both vaccines was
similarly favorable [7]. The safety and high immunogenicity of the
RTS,S/AS01 formulation was confirmed in malaria-exposed adults
in Kenya [22]. Here, the first use of RTS,S associated with the AS01
Adjuvant System in children is reported.
In the present study, both vaccines were well tolerated. In both
groups, patterns of non-serious and serious adverse events were in
accordance with general morbidity observed in this population.
There were no unsolicited adverse events related to vaccination.
Vaccination induced no hematological or biochemical abnormal-
ities. The vast majority of solicited symptoms consisted of mild
pain at the injection site, confirming results of previous RTS,S/
AS01 and RTS,S/AS02 studies. The frequency of local solicited
symptoms (pain and swelling) was dose related and progressively
increased from Dose 1 to 3 in both vaccines groups. This trend
had been reported in previous trials with RTS,S/AS02 [19,20], as
well as with other vaccines [23], showing that this is not specific to
the malaria candidate vaccine or specific Adjuvant System
technology, and is probably linked to a local reaction between
antigen and immune effectors like antibodies and primed T-cells.
Importantly, these reactions remained moderate in intensity even
after the third dose. In summary, all safety data generated in this
trial show that both formulations of the RTS,S/AS candidate
vaccine have a favorable safety profile. Larger studies are needed
to allow detection of potential rare events.
Our study clearly confirms our primary hypothesis, i.e., the
non-inferiority of RTS,S/AS01E compared to RTS,S/AS02D in
its ability to induce anti-CS antibodies. In fact, an early trend
towards higher anti-CS GMTs in recipients of RTS,S/AS01E was
found. The trend toward a stronger immune response using the
AS01E Adjuvant System was also observed for anti-HBsAg titers.
The results also show the enhancement effect of a third vaccine
dose compared to a two-dose regimen in eliciting an anti-CS
immune response. The relationship between anti-CS immune
response and protection induced against malaria is complex and
Figure 3. The effect of previous hepatitis B vaccination on anti-HBs antibodies. Boxplot graph of anti-HBs responses. Represents Q25,
median, Q75, highest and lowest observation below/above 1.5 times interquartile range and individual data points below/above 1.5 times
interquartile range. GMTs are indicated by +.
doi:10.1371/journal.pone.0007611.g003
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not yet fully characterized, as no protective threshold has been
defined. While a consistent association between higher (vs. lower)
anti-CS response and protection against P. falciparum infection was
seen in challenge studies [18,24,25] and in field trials with active
detection of infection [6], such an association was not found with
malaria disease, as captured in a passive case detection system [8].
More thorough investigation of immune responses to RTS,S/AS
candidate vaccines, including in efficacy studies, are underway and
may contribute to better characterisation of the relationship
between the immunity induced and protection.
According to national guidelines of Gabon, Hepatitis B vaccine
is administered routinely as part of the EPI programme. However,
supply chain ruptures, migration, and other factors lead to a
partial immunization of a large proportion of the population and
almost half of the children in this study had not received any
hepatitis B vaccine at recruitment. Interestingly, we found that
children with prior immunization against hepatitis B had a
stronger immune response post-vaccination not only against
HBsAg but against CS as well. Neonatal hepatitis B vaccination
may therefore be favorable to early RTS,S-induced protection
against malaria in case of integration of an RTS,S-based vaccine
in an EPI program that includes neonatal hepatitis B vaccination.
It is unclear how previous HBs-induced immune responses
enhance the CS-specific response but it is most likely related to the
covalently bound CS segment and HBs fusion protein present in
RTS,S. The following non exclusive hypothetical mechanisms
may occur: (i) circulating anti-HBs antibodies may be favorable to
CS antigen capture by antigen-presenting cells and following T-
cell and B-cell priming; (ii) HBs-primed B-cells expressing anti-
HBs surface antibodies may capture the RTS,S antigen and, given
their antigen presentation capacities, be efficient antigen present-
ing cells for CS-specific T-cell priming; (iii) HBs-specific CD4
memory T-cells induced by previous vaccination may provide
more rapid T-cell help to CS-specific B cells upon antigen re-
stimulation by the HBsAg present in RTS,S.
Having been previously vaccinated with at least one Hepatitis B
vaccine dose was associated with increased anti-HBs responses
post vaccination dose 2 and dose 3, with both RTS,S formulations,
indicating the absence of exhaustion of the immune response upon
repeated exposure to the HBs vaccine antigen.
As a result of the encouraging result of the present trial, given
the favorable safety profile and the indication of superior
immunogenicity of RTS,S/AS01E compared to RTS,S/AS02D,
further development of this vaccine candidate is ongoing. Studies
aiming at confirmation of safety, further age de-escalation,
schedule optimization, assessment of efficacy against malaria,
and interaction of RTS,S/AS01E with EPI vaccines are currently
being performed in various parts of Africa.
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